Author Info: 1- Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Ey

Author Info: 1- Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Eye Center of Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China 2- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou 311121, China 3- Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA 4- School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China 5- Lead contact

Author Info: (1) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA; Department of Biomedicine, University o

Author Info: (1) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA; Department of Biomedicine, University of Bergen, 5019 Bergen, Norway. (2) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA; Department of Neurosurgery, Leiden University Medical Center, 2300 RC Leiden, the Netherlands. (3) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (4) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (5) Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Institute of Medical Engineering and Sciences and Department of Chemistry, Massachusetts Institute Technology, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institutes of Technology, Cambridge, MA 02139, USA; Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada; Department of Human Genetics, McGill University, Montreal, QC, Canada. (6) Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02215, USA; Ludwig Center at Harvard Medical School, Boston, MA 02215, USA. (7) Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Cell Biology and Pathology, Harvard Medical School, Boston, MA 02215, USA; Ludwig Center at Harvard Medical School, Boston, MA 02215, USA; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. (8) Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (9) Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (10) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (11) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (12) Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. (13) Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. (14) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Harvard Medical School, Boston, MA 02115, USA. (15) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA; Department of Neurosurgery, Leiden University Medical Center, 2300 RC Leiden, the Netherlands. (16) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (17) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (18) Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. (19) Harvard-MIT Health Sciences and Technology, Cambridge, MA 02139, USA. (20) Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. (21) Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Mass General Cancer Center, Krantz Family Center for Cancer Research, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. (22) Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (23) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. (24) Molecular Neurogenetics Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA. Electronic address: kbreyne@mgh.harvard.edu.

Author Info: (1) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. Institute of Molecul

Author Info: (1) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. Institute of Molecular Medicine and Experimental Immunology, University Hospital Bonn, Bonn, Germany. (2) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (3) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (4) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (5) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (6) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. Immunogenomics and Neurodegeneration, Deutsches Zentrum fŸr Neurodegenerative Erkrankungen (DZNE), Bonn, Germany. (7) Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. (8) Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. (9) Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. (10) Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. (11) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (12) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (13) Institute of Molecular Medicine and Experimental Immunology, University Hospital Bonn, Bonn, Germany. (14) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (15) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (16) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (17) Immunogenomics and Neurodegeneration, Deutsches Zentrum fŸr Neurodegenerative Erkrankungen (DZNE), Bonn, Germany. (18) Genomics and Immunoregulation, LIMES Institute, University of Bonn, Bonn, Germany. (19) Department of Neuronal Control of Metabolism, Max Planck Institute for Metabolism Research, Cologne, Germany. (20) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (21) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (22) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (23) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (24) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. (25) Department of Microbiology, The Biomedical Discovery Institute, Monash University, Melbourne, Victoria, Australia. (26) Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. (27) Immunogenomics and Neurodegeneration, Deutsches Zentrum fŸr Neurodegenerative Erkrankungen (DZNE), Bonn, Germany. Systems Medicine, Deutsches Zentrum fŸr Neurodegenerative Erkrankungen (DZNE), Bonn, Germany. PRECISE Platform for Single Cell Genomics and Epigenomics, DZNE, University of Bonn, and West German Genome Center, Bonn, Germany (DZNE), Bonn, Germany. (28) Institute of Molecular Medicine and Experimental Immunology, University Hospital Bonn, Bonn, Germany. (29) Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Victoria, Australia. axel.kallies@unimelb.edu.au. Institute of Molecular Medicine and Experimental Immunology, University Hospital Bonn, Bonn, Germany. axel.kallies@unimelb.edu.au.

Author Info: (1) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. Electronic add

Author Info: (1) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. Electronic address: abachem@unimelb.edu.au. (2) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (3) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia; Centre for Pathogen Genomics Innovation Hub, Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (4) Computational Science Initiative, Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (5) Computational Science Initiative, Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (6) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (7) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (8) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia; Institute of Experimental Oncology, Medical Faculty, University Hospital Bonn, University of Bonn, Bonn, North Rhine-Westphalia 53127, Germany. (9) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (10) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (11) Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3000, Australia. (12) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (13) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (14) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (15) Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3168, Australia. (16) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (17) Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3000, Australia; Melanoma Discovery Laboratory, Harry Perkins Institute of Medical Research, Nedlands, WA 6009, Australia; School of Medicine, University of Western Australia, Crawley, WA 6009, Australia. (18) Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3000, Australia; Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. (19) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia; Melbourne Integrative Genomics, School of BioSciences, The University of Melbourne, Melbourne, VIC 3010, Australia. (20) Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3000, Australia. (21) Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3168, Australia. (22) School of Biomedical Sciences, The University of Western Australia, Perth, WA 6009, Australia; Telethon Kids Institute, The University of Western Australia, Perth, WA 6009, Australia. (23) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia; Centre for Pathogen Genomics Innovation Hub, Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (24) Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3000, Australia; Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia. (25) Computational Science Initiative, Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (26) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia. (27) Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia; Institute of Innate Immunity, University of Bonn, Bonn, North Rhine-Westphalia 53127, Germany. Electronic address: sbedoui@unimelb.edu.au.

Author Info: (1) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Max-DelbrŸck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Insti

Author Info: (1) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Max-DelbrŸck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany. (2) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Max-DelbrŸck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany. Institute for Systemic Inflammation Research (ISEF), University of LŸbeck, LŸbeck, Germany. (3) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Department of Neurology with Experimental Neurology, CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. (4) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Department of Neurology with Experimental Neurology, CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. (5) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Department of Neurology with Experimental Neurology, CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Einstein Center for Neurosciences Berlin (ECN) at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. (6) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Max-DelbrŸck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany. (7) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Max-DelbrŸck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany. Department of Biology, Chemistry, Pharmacy, Freie UniversitŠt Berlin, Berlin, Germany. Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA. (8) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Department of Neurology with Experimental Neurology, CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. NeuroCure Cluster of Excellence, CharitŽ UniversitŠtsmedizin Berlin, Berlin, Germany. (9) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Department of Neurology with Experimental Neurology, CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. NeuroCure Cluster of Excellence, CharitŽ UniversitŠtsmedizin Berlin, Berlin, Germany. (10) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. Department of Neurology with Experimental Neurology, CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. NeuroCure Cluster of Excellence, CharitŽ UniversitŠtsmedizin Berlin, Berlin, Germany. CharitŽ UniversitŠtsmedizin Berlin, Center for Stroke Research Berlin, Berlin, Germany. German Center for Neurodegenerative Diseases (DZNE), partner site Berlin, Berlin, Germany. German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany. German Center for Mental Health (DZPG), partner site Berlin, Berlin, Germany. (11) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany leif.ludwig@bih-charite.de samuel.knauss@charite.de. Department of Neurology with Experimental Neurology, CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany. (12) Berlin Institute of Health at CharitŽ - UniversitŠtsmedizin Berlin, Berlin, Germany leif.ludwig@bih-charite.de samuel.knauss@charite.de. Max-DelbrŸck-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin Institute for Medical Systems Biology (BIMSB), Berlin, Germany.

Author Info: (1) Onchilles Pharma Inc., San Diego, CA, USA. (2) Onchilles Pharma Inc., San Diego, CA, USA. (3) Onchilles Pharma Inc., San Diego, CA, USA. (4) Onchilles Pharma Inc., San Diego, C

Author Info: (1) Onchilles Pharma Inc., San Diego, CA, USA. (2) Onchilles Pharma Inc., San Diego, CA, USA. (3) Onchilles Pharma Inc., San Diego, CA, USA. (4) Onchilles Pharma Inc., San Diego, CA, USA. (5) South Coast Gynecologic Oncology Inc, San Diego, CA, USA. (6) Helen Diller Family Comprehensive Cancer Center, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA. (7) The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, UK. (8) Onchilles Pharma Inc., San Diego, CA, USA. (9) Onchilles Pharma Inc., San Diego, CA, USA. Electronic address: lbecker@onchillespharma.com.

Author Info: (1) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; Department of Thoracic Oncology, Lung Cancer Diagnosis and Tr

Author Info: (1) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100053, China. (2) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. (3) National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. (4) National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. (5) National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; Department of Endoscopy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. (6) National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. (7) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. (8) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. (9) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; Department of Thoracic Oncology, Lung Cancer Diagnosis and Treatment Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. (10) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. (11) Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China. (12) National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China. (13) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. (14) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. (15) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Electronic address: zhiyongliu@tjmuch.com. (16) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Electronic address: chenpeng@tjmuch.com. (17) Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; National Clinical Research Center for Cancer, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China. Electronic address: guohua@tjmuch.com.

Author Info: (1) Department of Bioengineering, Imperial College London, London, UK. (2) Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Division of Hematology/Oncology,

Author Info: (1) Department of Bioengineering, Imperial College London, London, UK. (2) Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. (3) Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. (4) Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. (5) Department of Bioengineering, Imperial College London, London, UK. (6) Department of Bioengineering, Imperial College London, London, UK. (7) Department of Bioengineering, Imperial College London, London, UK. (8) Department of Bioengineering, Imperial College London, London, UK. (9) Department of Bioengineering, Imperial College London, London, UK. (10) Department of Microbiology, Immunology and Molecular Genetics, UCLA, Duarte, CA, USA. (11) Department of Bioengineering, Imperial College London, London, UK. (12) Department of Bioengineering, Imperial College London, London, UK. (13) Department of Bioengineering, Imperial College London, London, UK. (14) Department of Bioengineering, Imperial College London, London, UK. (15) Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. (16) Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. (17) Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA. Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, CA, USA. (18) Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Division of Medical Oncology, University of Washington, Seattle, WA, USA. (19) Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. jklee@mednet.ucla.edu. Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. jklee@mednet.ucla.edu. Parker Institute for Cancer Immunotherapy at UCLA, Los Angeles, CA, USA. jklee@mednet.ucla.edu. (20) Department of Bioengineering, Imperial College London, London, UK. j.ishihara@imperial.ac.uk. Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Chiba, Japan. j.ishihara@imperial.ac.uk.

Author Info: (1) Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (2) Department of Genetics, Stanford University, Stanford, CA, USA. Department of Medicine, Sta

Author Info: (1) Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (2) Department of Genetics, Stanford University, Stanford, CA, USA. Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. (3) Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. (4) Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. (5) Proteas Health, Torrance, CA, USA. (6) Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (7) Department of Pathology, Stanford University, Stanford, CA, USA. (8) Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (9) Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (10) Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (11) Department of Radiation Oncology and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (12) Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. (13) Immunology Graduate Program, Stanford University School of Medicine, Stanford, CA, USA. Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. (14) Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. (15) Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. (16) Immuno-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. (17) Department of Pathology, Stanford University, Stanford, CA, USA. Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. (18) Department of Pediatrics, City of Hope National Medical Center, Duarte, CA, USA. Department of Immuno-oncology, City of Hope National Medical Center, Duarte, CA, USA. (19) Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. (20) Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. robbie_majzner@dfci.harvard.edu. Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. robbie_majzner@dfci.harvard.edu. Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA. robbie_majzner@dfci.harvard.edu. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. robbie_majzner@dfci.harvard.edu.

Author Info: (1) Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. (2) Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Am

Author Info: (1) Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. (2) Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. (3) Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands. (4) Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands. (5) Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands. (6) Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. (7) Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands. (8) Natera, Inc, Austin, TX, USA. (9) Natera, Inc, Austin, TX, USA. (10) Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. (11) Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands. (12) Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. (13) Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Oncode Institute, Utrecht, the Netherlands. (14) Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. (15) Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Oncode Institute, Utrecht, the Netherlands. Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands. (16) Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, the Netherlands. Oncode Institute, Utrecht, the Netherlands. (17) Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.chalabi@nki.nl. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. m.chalabi@nki.nl.